BioNTech SE · BNTX · FY2026 Q3 · Calendar Q4 2026
BioNTech raises 2026 revenue outlook as oncology pipeline advances
The quarter’s strongest strategic signal is BioNTech’s attempt to translate late-stage oncology progress into a broader multi-product business, while raised full-year revenue guidance provides near-term support. That case remains dependent on clinical execution and regulatory progress as COVID vaccine demand declines.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about BNTX FY2026 Q3
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, guidance sentiment shifted from lowered to raised, and the current call emphasized late-stage oncology evidence, combination regimens and expansion of global Phase III development. The analysis also highlights ongoing COVID vaccine revenue pressure and management transition.
Guidance delta
Management raised full-year 2026 revenue guidance to €1.7–1.9 billion, according to the current-quarter analysis. The prior-quarter analysis had described guidance as lowered, with a €1.6–1.9 billion range.
Key takeaways
- The current-quarter analysis reports Q3 revenue of €1.3 billion, with reduced COVID vaccine demand weighing on revenue.
- Management raised its full-year revenue guidance while advancing its oncology strategy.
- The call highlighted gotistobart and pumitamig data and broader combination-treatment development.
- The analysis describes BioNTech as maintaining substantial research investment while building a multi-product business.
Management priorities
- Advance pumitamig through planned global Phase III trials across multiple cancer types.
- Develop combination approaches and expand ADC programs, including Alpha-D and T-Pam.
- Continue mRNA cancer-vaccine programs and integrate InstaDeep into BioNTech operations.
Follow BNTX with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompany context
Snapshot as of publicationBioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors.…
Healthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| PFE Pfizer Inc. | FY2026 Q3 · Calendar Q4 2026 | — | -2.0% | Pfizer raises 2026 guidance as launched portfolio growth offsets longer-term pressures |
| TEVA Teva Pharmaceutical Industries Limited | FY2026 Q3 · Calendar Q4 2026 | — | +3.3% | Teva’s innovative portfolio grows as revenue guidance rises |
| FMS Fresenius Medical Care AG & Co. KGaA | FY2026 Q3 · Calendar Q4 2026 | — | -3.6% | Fresenius Medical Care cuts 2026 outlook as cost and reimbursement pressure persist |
| RVTY Revvity, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +10.8% | Revvity Raises FY2026 Outlook After 7% Q3 Organic Growth |
| WAT Waters Corporation | FY2026 Q3 · Calendar Q4 2026 | — | +3.8% | Waters Raises FY2026 Revenue Outlook as Organic Growth Accelerates |
| HSIC Henry Schein, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +0.0% | Henry Schein raises 2026 EPS outlook as U.S. dental sales grow |
Latest beats and misses
Who reports nextBeat on EPS
- FANGFY2026 Q3 · November 2, 2026+2.4% EPS-3.7% move
- RRXFY2026 Q3 · November 3, 2026+41.1% EPS+11.8% move
- UDRFY2026 Q3 · November 2, 2026+340.8% EPS+0.1% move
- VNOMFY2026 Q3 · November 2, 2026+3.9% EPS-2.6% move
- EQH-PAFY2026 Q3 · November 2, 2026+14.5% EPS— move
- WMBFY2026 Q3 · November 2, 2026+0.2% EPS+3.5% move
Get the BNTX recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-11-03T20:10:54.584038+00:00
- FN2 earnings calendar · 2026-11-03T01:23:13.143323+00:00
- Polygon adjusted daily market bars · 2026-11-03T21:50:46.869222+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-03T21:50:46.866499+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-03. For educational purposes only; not investment advice.